Marksans Pharma Limited — Others, 08-08-2025: Shareholders meeting

Marksans Pharma's 33rd Annual General Meeting successfully concluded with all resolutions approved by shareholders. Members adopted the audited standalone and consolidated financial results for the financial year ended March 31, 2025. An equity dividend of Rs. 0.80 per share was also approved. Key governance approvals included the re-appointment of Mrs. Sandra Saldana as Director, Mr. Srinivas Mishra as an Independent Director, and M/s Jinesh Dedhia & Associates as secretarial auditor. Additionally, amendments to the Employee Stock Option Scheme 2024 were approved, allowing grants to subsidiary employees. Mr. Mark Saldanha was also re-appointed as Managing Director for five years.